The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

发表在《新英格兰医学杂志》的CLOSURE-AF研究表明，对于脑卒中与出血高危房颤患者，左心耳封堵术在脑卒中、全身栓塞、大出血、心血管/不明原因死亡的复合终点方面，未优于最优药物治疗方案。

For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and ...

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and remains a significant contributor to morbidity and mortality worldwide. A central focus of current research is the left ...

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...